Treatment of Acute Myeloid Leukemia in the Community Setting
Abstract The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a vir...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2024-09, Vol.29 (9), p.801-805 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 805 |
|---|---|
| container_issue | 9 |
| container_start_page | 801 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 29 |
| creator | Al-Juhaishi, Taha Dela Cruz, Servillano Gupta, Rohan Keiffer, Gina Morrison, Vicki A Shapira, Iuliana Woods, Ashley Norsworthy, Kelly de Claro, Romeo Angelo Theoret, Marc R Garg, Ravin Pulte, Elizabeth Dianne |
| description | Abstract
The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.
The FDA held a virtual symposium on acute myeloid leukemia (AML) treatment in the community in November 2022 to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here. |
| doi_str_mv | 10.1093/oncolo/oyae051 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11379644</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A811852539</galeid><oup_id>10.1093/oncolo/oyae051</oup_id><sourcerecordid>A811852539</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-6b93f8aa3f9c510726f3870b8b04f76bf283ca83217b099daa97f160a08c89fb3</originalsourceid><addsrcrecordid>eNqFkc1r3DAQxUVpyMcm1x6LoZfm4GRk2ZYEhbIsbRPY0EM3kJuQtaONWlva2HJh__so7GZJIBB00GP0m8doHiGfKFxQkOwyeBPacBk2GqGiH8gxrUqZlxLuPiYNguWcVvKInAzDX4AkWXFIjphMCoAdk2-LHnXs0Mcs2GxqxojZzQbb4JbZHMd_2DmdOZ_Fe8xmoetG7-Im-4MxOr86JQdWtwOe7e4Juf35YzG7yue_f13PpvPcMM5jXjeSWaE1s9JUFHhRWyY4NKKB0vK6sYVgRgtWUN6AlEutJbe0Bg3CCGkbNiHft77rselwadK0vW7Vuned7jcqaKdev3h3r1bhv6KUcVmXZXL4unPow8OIQ1SdGwy2rfYYxkExkKUooEg7mZAvW3SlW1TO25AszROupoJSURUVk4m6eINKZ5k2ZoJH61L9rQbTh2Ho0e7Hp6CeolTbKNUuytTw-eWn9_hzdgk43wJhXL9n9ghRwqmx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3094820200</pqid></control><display><type>article</type><title>Treatment of Acute Myeloid Leukemia in the Community Setting</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Free E-Journal (出版社公開部分のみ）</source><source>Oxford Open</source><source>PubMed Central</source><creator>Al-Juhaishi, Taha ; Dela Cruz, Servillano ; Gupta, Rohan ; Keiffer, Gina ; Morrison, Vicki A ; Shapira, Iuliana ; Woods, Ashley ; Norsworthy, Kelly ; de Claro, Romeo Angelo ; Theoret, Marc R ; Garg, Ravin ; Pulte, Elizabeth Dianne</creator><creatorcontrib>Al-Juhaishi, Taha ; Dela Cruz, Servillano ; Gupta, Rohan ; Keiffer, Gina ; Morrison, Vicki A ; Shapira, Iuliana ; Woods, Ashley ; Norsworthy, Kelly ; de Claro, Romeo Angelo ; Theoret, Marc R ; Garg, Ravin ; Pulte, Elizabeth Dianne</creatorcontrib><description>Abstract
The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.
The FDA held a virtual symposium on acute myeloid leukemia (AML) treatment in the community in November 2022 to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.</description><identifier>ISSN: 1083-7159</identifier><identifier>ISSN: 1549-490X</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyae051</identifier><identifier>PMID: 39159003</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Community medicine ; Hematologic Malignancies ; Humans ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - therapy ; Methods ; United States</subject><ispartof>The oncologist (Dayton, Ohio), 2024-09, Vol.29 (9), p.801-805</ispartof><rights>The Author(s) 2024. Published by Oxford University Press. Elements of this work have been written by employees of the US Federal Government. 2024</rights><rights>The Author(s) 2024. Published by Oxford University Press. Elements of this work have been written by employees of the US Federal Government.</rights><rights>COPYRIGHT 2024 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-8359-0178</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379644/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379644/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1598,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39159003$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Juhaishi, Taha</creatorcontrib><creatorcontrib>Dela Cruz, Servillano</creatorcontrib><creatorcontrib>Gupta, Rohan</creatorcontrib><creatorcontrib>Keiffer, Gina</creatorcontrib><creatorcontrib>Morrison, Vicki A</creatorcontrib><creatorcontrib>Shapira, Iuliana</creatorcontrib><creatorcontrib>Woods, Ashley</creatorcontrib><creatorcontrib>Norsworthy, Kelly</creatorcontrib><creatorcontrib>de Claro, Romeo Angelo</creatorcontrib><creatorcontrib>Theoret, Marc R</creatorcontrib><creatorcontrib>Garg, Ravin</creatorcontrib><creatorcontrib>Pulte, Elizabeth Dianne</creatorcontrib><title>Treatment of Acute Myeloid Leukemia in the Community Setting</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Abstract
The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.
The FDA held a virtual symposium on acute myeloid leukemia (AML) treatment in the community in November 2022 to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.</description><subject>Community medicine</subject><subject>Hematologic Malignancies</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Methods</subject><subject>United States</subject><issn>1083-7159</issn><issn>1549-490X</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqFkc1r3DAQxUVpyMcm1x6LoZfm4GRk2ZYEhbIsbRPY0EM3kJuQtaONWlva2HJh__so7GZJIBB00GP0m8doHiGfKFxQkOwyeBPacBk2GqGiH8gxrUqZlxLuPiYNguWcVvKInAzDX4AkWXFIjphMCoAdk2-LHnXs0Mcs2GxqxojZzQbb4JbZHMd_2DmdOZ_Fe8xmoetG7-Im-4MxOr86JQdWtwOe7e4Juf35YzG7yue_f13PpvPcMM5jXjeSWaE1s9JUFHhRWyY4NKKB0vK6sYVgRgtWUN6AlEutJbe0Bg3CCGkbNiHft77rselwadK0vW7Vuned7jcqaKdev3h3r1bhv6KUcVmXZXL4unPow8OIQ1SdGwy2rfYYxkExkKUooEg7mZAvW3SlW1TO25AszROupoJSURUVk4m6eINKZ5k2ZoJH61L9rQbTh2Ho0e7Hp6CeolTbKNUuytTw-eWn9_hzdgk43wJhXL9n9ghRwqmx</recordid><startdate>20240906</startdate><enddate>20240906</enddate><creator>Al-Juhaishi, Taha</creator><creator>Dela Cruz, Servillano</creator><creator>Gupta, Rohan</creator><creator>Keiffer, Gina</creator><creator>Morrison, Vicki A</creator><creator>Shapira, Iuliana</creator><creator>Woods, Ashley</creator><creator>Norsworthy, Kelly</creator><creator>de Claro, Romeo Angelo</creator><creator>Theoret, Marc R</creator><creator>Garg, Ravin</creator><creator>Pulte, Elizabeth Dianne</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8359-0178</orcidid></search><sort><creationdate>20240906</creationdate><title>Treatment of Acute Myeloid Leukemia in the Community Setting</title><author>Al-Juhaishi, Taha ; Dela Cruz, Servillano ; Gupta, Rohan ; Keiffer, Gina ; Morrison, Vicki A ; Shapira, Iuliana ; Woods, Ashley ; Norsworthy, Kelly ; de Claro, Romeo Angelo ; Theoret, Marc R ; Garg, Ravin ; Pulte, Elizabeth Dianne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-6b93f8aa3f9c510726f3870b8b04f76bf283ca83217b099daa97f160a08c89fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Community medicine</topic><topic>Hematologic Malignancies</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Methods</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Juhaishi, Taha</creatorcontrib><creatorcontrib>Dela Cruz, Servillano</creatorcontrib><creatorcontrib>Gupta, Rohan</creatorcontrib><creatorcontrib>Keiffer, Gina</creatorcontrib><creatorcontrib>Morrison, Vicki A</creatorcontrib><creatorcontrib>Shapira, Iuliana</creatorcontrib><creatorcontrib>Woods, Ashley</creatorcontrib><creatorcontrib>Norsworthy, Kelly</creatorcontrib><creatorcontrib>de Claro, Romeo Angelo</creatorcontrib><creatorcontrib>Theoret, Marc R</creatorcontrib><creatorcontrib>Garg, Ravin</creatorcontrib><creatorcontrib>Pulte, Elizabeth Dianne</creatorcontrib><collection>Oxford Open</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Juhaishi, Taha</au><au>Dela Cruz, Servillano</au><au>Gupta, Rohan</au><au>Keiffer, Gina</au><au>Morrison, Vicki A</au><au>Shapira, Iuliana</au><au>Woods, Ashley</au><au>Norsworthy, Kelly</au><au>de Claro, Romeo Angelo</au><au>Theoret, Marc R</au><au>Garg, Ravin</au><au>Pulte, Elizabeth Dianne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Acute Myeloid Leukemia in the Community Setting</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2024-09-06</date><risdate>2024</risdate><volume>29</volume><issue>9</issue><spage>801</spage><epage>805</epage><pages>801-805</pages><issn>1083-7159</issn><issn>1549-490X</issn><eissn>1549-490X</eissn><abstract>Abstract
The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.
The FDA held a virtual symposium on acute myeloid leukemia (AML) treatment in the community in November 2022 to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>39159003</pmid><doi>10.1093/oncolo/oyae051</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-8359-0178</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2024-09, Vol.29 (9), p.801-805 |
| issn | 1083-7159 1549-490X 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11379644 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Free E-Journal (出版社公開部分のみ）; Oxford Open; PubMed Central |
| subjects | Community medicine Hematologic Malignancies Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - therapy Methods United States |
| title | Treatment of Acute Myeloid Leukemia in the Community Setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T02%3A09%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Acute%20Myeloid%20Leukemia%20in%20the%20Community%20Setting&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Al-Juhaishi,%20Taha&rft.date=2024-09-06&rft.volume=29&rft.issue=9&rft.spage=801&rft.epage=805&rft.pages=801-805&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyae051&rft_dat=%3Cgale_pubme%3EA811852539%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3094820200&rft_id=info:pmid/39159003&rft_galeid=A811852539&rft_oup_id=10.1093/oncolo/oyae051&rfr_iscdi=true |